Target intelligence / Profile preview

F-box protein 44 (FBXO44)

Target
FBXO44
Molecular classification
F-box protein, Substrate recognition subunit of SCF E3 ubiquitin ligase complex, Member of the FBA family (F-box associated; G-domain containing), E3 ubiquitin ligase complex component
01

Overview

F-box protein 44 (FBXO44) is a substrate recognition subunit of the SCF (SKP1-CUL1-F-box protein) and CRL4B (CUL4B-DDB1-F-box protein) E3 ubiquitin ligase complexes, facilitating the ubiquitination and proteasomal degradation of specific substrates. Unlike other FBA family members, FBXO44 does not bind glycosylated proteins but instead recognizes substrates including BRCA1, a key regulator of DNA repair and cell cycle control, and RGS2, a regulator of G-protein signaling. FBXO44 plays critical roles in cellular protein turnover and is implicated in diseases such as breast and ovarian cancer (via BRCA1 regulation) and hypertension and anxiety (via RGS2 regulation). Although no approved drugs are known to target FBXO44 directly, its involvement in disease-associated pathways makes it an attractive therapeutic target.

Other names
F-box only protein 44FBG3FBX30FBX6AFBXO6AMGC14140Fbxo6aFbx44F-box protein FBX30F-box/G-domain protein 3F-box gene 3
02

Mechanism of action

Drugs targeting FBXO44 would act by inhibiting its E3 ligase catalytic activity, thereby preventing the ubiquitination and degradation of target proteins such as RGS2 and BRCA1

03

Biological functions

Substrate recognition for ubiquitin-mediated protein degradationRegulation of protein stability (e.g., BRCA1, RGS2)Control of cell cycle and DNA repair processes (via BRCA1)Potential involvement in antigen processing and presentation
04

Disease associations

Cancer (notably breast and ovarian cancer via BRCA1 regulation)Hypertension and anxiety (via RGS2 degradation)Congenital disorder of deglycosylation 1
05

Safety considerations

Off-target effects on protein degradation pathways (possible unanticipated modulation of cell cycle, DNA repair, or signaling proteins)Dysregulation of BRCA1 or RGS2 can lead to tumorigenesis or altered cardiovascular/neuropsychiatric physiology
06

Interacting drugs

No clinically approved drugs are documented to target FBXO44 directly as of current literature; however, pharmacological inhibition of FBXO44’s E3 ligase activity is proposed as a therapeutic strategy in hypertension, anxiety, and cancer
07

Biomarkers

FBXO44 expression levels (potential marker for breast cancer prognosis)BRCA1 protein levels (indicator of FBXO44 activity/target engagement)RGS2 protein stability (potential pharmacodynamic marker)

Beyond the preview

Go deeper on F-box protein 44 (FBXO44).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on F-box protein 44 (FBXO44).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call